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Abstract
Background: Thrombolysis with intravenous rt-PA is currently the only approved acute therapy for ischemic stroke. Re-
occlusion after initial recanalization occurs in up to 34% in patients treated with rt-PA, probably caused by platelet 
activation. In acute myocardial infarction, the combination of thrombolysis and antiplatelet therapy leads to a greater 
reduction of mortality compared to thrombolysis alone. In patients with acute ischemic stroke, several studies showed 
that patients already on antiplatelet treatment prior to thrombolysis had an equal or even better outcome compared 
to patients without prior antiplatelet treatment, despite an increased risk of intracerebral bleeding. Based on the fear of 
intracerebral haemorrhage, current international guidelines recommend postponing antiplatelet therapy until 24 
hours after thrombolysis. Remarkably, prior use of antiplatelet therapy is not a contra-indication for thrombolysis. We 
hypothesize that antiplatelet therapy in combination with rt-PA thrombolysis will improve outcome by enhancing 
fibrinolysis and preventing re-occlusion.
Methods/Design: ARTIS is a randomised multi-center controlled trial with blind endpoint assessment. Our objective is 
to investigate whether immediate addition of aspirin to rt-PA thrombolysis improves functional outcome in ischemic 
stroke. Patients with acute ischemic stroke eligible for rt-PA thrombolysis are randomised to receive 300 mg aspirin 
within 1.5 hours after start of thrombolysis or standard care, consisting of antiplatelet therapy after 24 hours. Primary 
outcome is poor functional health at 3 months follow-up (modified Rankin Scale 3 - 6).
Discussion: This is the first clinical trial investigating the combination of rt-PA and acute aspirin by means of a simple 
and cheap adjustment of current antiplatelet regimen. We expect the net benefit of improved functional outcome will 
overcome the possible slightly increased risk of intracerebral haemorrhage.
Trial registration: The Netherlands National Trial Register NTR822. The condensed rationale of the ARTIS-Trial has 
already been published in Cerebrovascular Diseases.
Background
Stroke is an important cause of death and acquired dis-
ability in industrial world. In the large majority of isch-
emic strokes, cerebral arteries become occluded either by
a cardiac embolus or by thrombus formation in athero-
sclerotic vessel walls. The process of thrombus formation
is initiated by two separate but interacting mechanisms:
fibrin formation and platelet activation. Current standard
treatment in acute ischemic stroke with intravenous
recombinant tissue plasminogen activator (rt-PA) aims at
breaking down the fibrin cloth in order to restore
recanalisation of the occluded artery. Rt-PA treatment
results in an absolute 10% reduction of poor outcome
c o m p a r e d  t o  p l a c e b o  [ 1 ] .  H o w e v e r ,  b e n e f i t  f r o m  t h i s
treatment rapidly declines over time after symptom
onset. The number needed to treat to have 1 patient with
favourable outcome is 4-5 if treatment is started within
90 minutes after symptom onset as compared to controls
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[2], while this number increases to 14 if treatment is
started between 3 to 4.5 hours after symptom onset [2,3].
Within this current time window, early recanalisation is
strongly associated with improved functional outcomes
and reduced mortality [4,5]. Unfortunately, recanalisation
with intravenous rt-PA is only modest. The overall
recanalisation rate observed in 14 pooled intravenous
thrombolysis studies was only 43% [5], partly due to re-
occlusion. In continuous transcranial Doppler monitor-
ing studies, re-occlusion occurs in 20 - 34% of rt-PA
treated patients at a mean time of 65 minutes after start
of treatment [6,7]. Moreover, these studies show that re-
occlusion accounts for two thirds of the observed clinical
deterioration after initial improvement. A recent study
confirmed the association between re-occlusion and clin-
ical deterioration and showed that early re-occlusion is
highly predictive of long-term poor outcome [8].
Re-occlusion after initial recanalisation is probably ini-
tiated by increased platelet activation. Thrombolytic
therapy strongly activates the coagulation cascade leading
to thrombin formation, a potent platelet activator [9].
This haemostatic activation is maximal at 2 hours after
initiation of rt-PA treatment [10]. Exposure of the lipid
core of a disintegrating thrombus also leads to increased
platelet aggregation. These activated platelets induce
secretion of plasminogen activator inhibitor-1, which has
been shown to be the responsible factor in t-PA resis-
tance to lysis in platelet rich arterial thrombi [11].
Among all antiplatelet drugs, aspirin (acetylsalicylic
acid) is the most widely used drug. Inhibition of platelet
aggregation by aspirin is caused by the irreversible acety-
lation of cyclo-oxygenase 1 and inhibition of prostaglan-
din thromboxane A2. Aspirin has a rapid onset of action
resulting in substantial elimination of activated platelets.
In myocardial infarction, large clinical trials have
shown that adding aspirin to thrombolysis prevents re-
occlusion thereby improving outcome considerably. The
results of the second International Study of Infarct Sur-
vival Trial (ISIS-2) showed that mortality was reduced by
42% if patients were treated with streptokinase in combi-
nation with aspirin while mortality was reduced by only
25% if patients were treated with streptokinase alone [12].
Aspirin is therefore the standard adjunctive treatment in
acute myocardial infarction.
In acute ischemic stroke, the Multicenter Acute Stroke
Trial - Italy (MAST-I) duplicated the design of the ISIS 2
and showed an absolute risk reduction of 14% for disabil-
ity in patients treated with the combination of streptoki-
nase and aspirin as compared streptokinase alone. This
overall net benefit overcame an excess mortality rate
which was observed in the combination group. Symp-
tomatic intracerebral haemorrhages (SICH) largely con-
tributed to this increased mortality rate [13]. Meta-
analysis of the streptokinase trials confirmed a positive
effect on functional outcome with concomitant use of
aspirin that compensated for higher mortality rates [14].
Besides the high dosage of streptokinase used in these tri-
als, its non-fibrin-selectivity is nowadays generally held
responsible for the high number of SICH observed in this
study.
The addition of aspirin to rt-PA, which is a fibrin-selec-
tive thrombolytic agent, has never been investigated pro-
spectively. In the protocol of the Neurological Institute of
Neurological Disorders and Stroke (NINDS) Trial the use
of antiplatelet agents was postponed for 24 hours after rt-
PA treatment to prevent possible bleeding complications
[15]. However, the protocol did allow enrolling patients
already on antiplatelet drugs. Current guidelines adopted
these trial criteria for fear of SICH [16].
Subgroup analysis of the NINDS-trial reveals that
patients with prior aspirin use had a better outcome, with
lower frequencies of clinical deterioration and the same
SICH rate as compared to patients without previous aspi-
rin use [17]. Regarding the association between clinical
deterioration and the occurrence of vessel re-occlusion in
ischemic stroke [6,8] and the lower incidence of clinical
deterioration in patients with antiplatelet pre-treatment
[17], one might suggest that previous antiplatelet therapy
prevents re-occlusion. This hypothesis is supported by
the observation from recent prospective cohort studies,
which confirm this favourable outcome after thromboly-
sis in patients with prior use of antiplatelet drugs [18,19].
Based on all these observations we hypothesize that
immeditate addition of antiplatelet therapy to rt-PA in
acute ischemic stroke improves outcome by enhancing
clot lysis and preventing re-occlusion after initial recanal-
isation.
Methods and Design
Study design and objective
The Antiplatelet therapy in combination with Recombi-
nant t-PA Thrombolys in Ischemic Stroke (ARTIS) Trial
is a multi-center, prospective open, randomised con-
trolled trial with blind endpoint assessment (PROBE-
design). We compare direct addition of 300 mg aspirin to
intravenous rt-PA thrombolysis for ischemic stroke ver-
sus standard thrombolysis care, in which antiplatelet
drugs are usually delayed by 24 hours after rt-PA. All par-
ticipating centres are experienced in thrombolytic treat-
ment for acute stroke.
The primary objective of the ARTIS-Trial is to investi-
gate whether the addition of asprin to standard rt-PA
thrombolysis reduces poor outcome in acute ischemic
stroke. Poor outcome is defined as death or dependency
assessed by the modified Rankin Scale (mRS, score 3-6) at
3 months follow-up.Zinkstok et al. Trials 2010, 11:51
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Enrolment procedures
The study population are acute ischemic stroke patients
who present at participating centres and are treated with
intravenous (IV) thrombolysis with rt-PA. Patients aged
18 years or older can be enrolled. Patients will be asked
for written informed consent. The trial itself has no other
firm exclusion criteria than those established by the judg-
ment of the individual treating physician using local pro-
tocols for IV rt-PA treatment. When the patient has a
diminished decision-making capacity as result of the
stroke (e.g. aphasia), informed consent will be obtained
from a representative of the patient. Exclusion of these
patients would lead to a selective patient sample. Patients
are also excluded if they have:
▪ known antiplatelet therapy in the previous 5 days (in
case of uncertainty the patient may be included);
▪ known thrombocytopenia or thrombocyte count <
100 * 10E9/l;
▪ known contra-indications to acetylsalicylic acid treat-
ment;
▪ known anticogualant therapy in the previous 5 days;
▪ known legal incompetence of the patient prior to this
stroke.
Randomisation
Randomisation will be performed per participating cen-
tre to ensure a equal distribution of patients between
both group. The randomisation procedure will be com-
puter- and web based, using permuted blocks. Randomis-
ation will be stratified by centre, age (≤ 60 years, > 60
years), gender and the time between symptom onset and
time of rt-PA bolus (< 2 hours, 2-3 hours, > 3 hours).
Intervention
In order to prevent delay of start of thrombolytic treat-
ment, informed consent and randomisation procedures
will be performed as soon as continuous infusion of rt-PA
(0.9 mg/kg) has started after bolus administration (10%)
Patients allocated to the active group will receive 300 mg
aspirin (Aspégic®) as lysine salt intravenous as bolus.
Since there is a peak in platelet activation after 2 hours
after initiation of rt-PA thrombolysis [10], aspirin will be
administered within 1.5 hours after the rt-PA bolus.
Patient and treating physician are not blinded for treat-
ment allocation.
We choose to apply aspirin intravenously for two rea-
sons. First, onset of action has to be as soon as possible as
re-occlusion starts to occur soon after rt-PA administra-
tion [6,7]. Intravenous aspirin leads to faster platelet sup-
pression than oral aspirin, which results in a widely
varying uptake [20]. Aspirin may be given simultaneous
with the rt-PA continuous infusion, preferably through a
different intravenous line. In case of only one intravenous
access, rt-PA infusion has to be shortly interrupted in
order to administer aspirin through this line with saline
flushing before and afterwards.
Second, intravenously administration enables patients
having swallowing difficulties caused by their stroke to be
included. Exclusion of this subgroup would make the trial
prone to inclusion bias.
Investigational medicinal product
Aspirin intravenous is registered in the Netherlands as
Aspégic® (Sanofi-Synthelabo BV). Thrombocyte aggrega-
tion is irreversibly reduced by this calcium-ureum-salt,
causing longer coagulations times. Aspirin use may lead
to gastro-intestinal reactions. However, due to the single
use adverse reactions caused by the trial medication are
expected to be limited.
Alteplase® (Boehringer Ingelheim GmbH) is essential
and important co-medication in the ARTIS-Trial. Inter-
action of Aspégic® with rt-PA is unknown, although rt-PA
treatment might increase the risk of intracerebral bleed-
ing in aspirin pre-treated stroke patients. The character-
istics of rt-PA may therefore influence our results even
though rt-PA itself is not under investigation.
Recommendations concerning rt-PA treatment
Patients will receive rt-PA treatment in both groups
according to local protocols at participating centres. Rec-
ommendations of rt-PA treatment concerning hyperten-
sion and thrombocyte count are based on standard
international guidelines [16]. Blood pressure should not
be lowered with medication prior to rt-PA treatment. If
during rt-PA administration blood pressure rises above
180 mmHg systolic or 105 mmHg diastolic it is recom-
mended to administer 10 mg labetalol intravenous within
1-2 minutes. This should be repeated every 10-20 min-
utes until blood pressure is below 180 mmHg systolic or
below 105 mmHg diastolic. 150 mg labetalol is the maxi-
mum doses in 24 hours. During this treatment blood
pressure should be measured every 15 minutes. If the
blood pressure does not respond to labetalol, iv nitrop-
russide 0,5-10 μg/kg/minute should be added, with con-
tinuous blood pressure monitoring. In case the diastolic
blood pressure is above 140 mmHg nitroprusside should
be administered immediately as stated above. Thrombo-
cyte count is not necessary before starting rt-PA treat-
ment unless a patient is known with thrombocytopenia
[21]. Deviations from these recommendations are not
regarded as protocol violations, but will be registered.
Concomittant medication and secondary prophylaxis
All medication used before the stroke may be continued,
except anticoagulance. Standard secondary prophylaxis is
recommended according to the following scheme:
▪ carbasalate calcium 300 mg - once/daily - 24 hours
after rt-PA for 14 daysZinkstok et al. Trials 2010, 11:51
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▪ carbasalate calcium 100 mg - once/daily - 14 days
after rt-PA
▪ simvastatine 40 mg - once/daily - 0-24 hours after rt-
PA
▪ dipyridamole 200 mg - twice/daily - 24 hours after rt-
PA
Additional anti-diabetic or antihypertensive medica-
tion may be started as regarded appropriate by the treat-
ing physician.
Outcome measures
T h e  p r i m a r y  e n d p o i n t  i s  p o o r  f u n c t i o n a l  h e a l t h  a t  3
months defined as dependency or death (mRS 3 - 6).
The secondary objectives are:
▪ complications within 48 hours after randomisation
including the occurrence of SICH and serious systemic
bleeding. SICH is defined as CT-documented haemor-
rhage and a clinical deterioration leading to 4 or more
points increase on the National Institute of Health Stroke
Scale (NIHSS) as compared to the best score on the
NIHSS since admission. Serious systemic bleeding is
defined as a potentially life threatening bleeding which
requires immediate medical intervention;
▪ neurological symptoms quantified by the NIHSS 7 -
10 days after randomisation or at discharge if the
patient is discharged within 7 days;
▪ survival at 3 months;
▪ disability at 3 months assessed by the AMC Linear
Disablility Scale;
▪ functional health at 3 months non-dichotomized
(ordinal mRS);
▪ causes of poor outcome.
Data collection
At baseline following patient characteristics are collected
at each participating site: age, sex, ethnicity, medical his-
tory, pre-stroke medication, pre-stroke mRS, blood pres-
sure, Glasgow Coma Scale (GCS), National Institutes of
Health Stroke Scale (NIHSS), time of symptom onset, rt-
PA bolus and (if applicable) trial medication, thrombo-
cyte count and coagulation-International Normalized
Ratio. Baseline CT-scans will be collected from partici-
pating centres and assessed blindly centrally at the coor-
dinating centre for dens media sign, early ischemic
changes and degree of leukoariosis by an independent
blinded neuro-radiologist.
At follow-up, neurological deficits are assessed by the
NIHSS at 7-10 days or at discharge, if this is before 7 days.
Clinical deterioration, defined as a 4 or more points
increase on the NIHSS, will be followed by CT-scan and
registration as (serious) adverse events including possible
cause by each participating site. This CT-scan will be
assessed at the coordinating centre as well.
Primary outcome will be assessed by a blind research
nurse from the clinical trial office of the coordinating
centre, who will score the mRS by telephone using a
structured interview. To increase the inter-observer reli-
ability the number of research nurses will be limited to a
maximum of three. Disability will be assessed by the same
research nurse during the same telephone interview using
the Amsterdam Linear Disability Scale [22]. See Addi-
tional file 1 for all data collection forms.
In patients with a poor outcome at three months, the
Data Collection Committee composed of the investiga-
tors of the coordinating centre and the local investigator,
judges whether this poor outcome is attributed to the ini-
tial ischemic stroke, reported adverse event or other
causes.
Safety reporting
All adverse event reported by the subjects or observed by
the treating physicians will be recorded. In case of serious
adverse events (SAE), the principal investigator will be
notified by email or telephone within 24 hours. The prin-
cipal investigator subsequently reports SAE to the Data
Safety Monitoring Board (DSMB). This is an independent
committee of trial experts, who will focus on both safety
monitoring and analysis of effectiveness on unblinded
data. The DSMB will perform ongoing safety surveil-
lances, especially with regard to the occurrence of serious
adverse events in terms of SICH and serious systemic
bleeding within 48 hours. The DSMB can recommend
the Steering Committee of the ARTIS-Trial to terminate
the trial when there is clear and substantial evidence of
harm. All SAE will be reported to the central METC
according to their requirements as well.
Trial size
Based on our own experience in the stroke unit cohort
and the results of the rt-PA thrombolysis trials [1] and the
SITS-MOST registry [23] it is expected that 50% of the
patients with an ischemic stroke treated with rt-PA
thrombolysis will have a poor outcome (mRS 3-6). We
a i m  t o  r e d u c e  t h i s  p e r c e n t a g e  b y  1 0 % ,  a  r e l a t i v e  r i s k
reduction of 20%.
A two group X2 test with a 0,05 two-sided significance
level will have 80% power to detect the difference
between the control group proportion of 0,50 and an
experimental group proportion of 0,40 (odds ratio of
0,667) when the sample size in each group is 400 (total
trial size 800). With this sample size, a two-sided 95%
confidence interval for the difference between the pro-
portions will extend 0,069 from the observed difference
in proportions. With this sample size we are also able to
statistically detect a minimal effect size (difference
between mean scores of both treatment arms divided byZinkstok et al. Trials 2010, 11:51
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the SD of the control group ) of d = 0,20 as benchmark for
assessing the relative magnitude of score differences on
the continuous AMC Linear Disability Scale (ALDS)
which is a secondary outcome parameter.
Statistical analyses
Baseline characteristics will be summarized using
descriptive statistics. The main analysis of this trial con-
sists of a single comparison between the trial medication
groups of the primary outcome after three months
(dichotomized Rankin score). The analysis will be based
on the intention-to-treat principle. The effect size will be
expressed in a relative risk (RR) estimates and absolute
risk reduction (ARR). Additionally the primary outcome
will be analyzed using multivariate logistic regression,
adjusting (if necessary) for clinically relevant baseline
imbalances. The differences between NIHSS, ALDS
scores and non-dichotomized mRS will be analyzed using
the two-group t-test, the Mann-Whitney test, linear
regression and ordinal logistic regression, when appropri-
ate. The remaining secondary outcomes will be analyzed
using simple 2 × 2 tables and logistic regression. In all
analyses, statistical uncertainty will be quantified via 95%
confidence intervals.
Interim analysis
Besides interim analyses on the safety data the DSMB will
also perform an unblinded interim analysis on the pri-
mary outcome to assess the strength of the efficacy data
when half of the patients are enrolled. The DSMB will
also check the assumptions for sample size calculations.
The analysis will be performed by an independent statis-
tician of the Academic Medical Centre Clinical Research
Unit, who is not involved in managing the trial. The
DSMB can recommend the Steering Committee of the
ARTIS-Trial to
▪ adjust the sample size;
▪ early terminate the study when there is clear and sub-
stantial evidence of benefit;
▪ early terminate the study in case the data suggests no
benefit or in case accrual rates are too low to provide
adequate statistical power for identifying the primary
endpoint.
Predefined subgroup-analysis
With respect to the primary outcome a predefined sub-
group-analyses will be performed:
▪ rt-PA treatment < 2 hours versus 2-3 hours versus > 3
hours from symptom onset Effectiveness of IV
thrombolysis declines over time from symptom onset
probably caused by an increase in clot stability.
Regarding clot dissolution and reocclusion the bene-
f i c i a l  e f f e c t  o f  a d d i n g  a n t i p l a t e l e t  t h e r a p y  m i g h t
therefore be different over time. The risk of bleeding
can also change over time [2].
▪ trial medication within 1 hour versus between 1-1.5
hours from rt-PA bolus. Reocclusion occurs at a
median time of 65 minutes after start of rt-PA treat-
ment. Administration of Aspegic in the first hour
after the start of rt-PA treatment is therefore
expected to result in better outcome [6].
▪ based on ethnicity differences: whites versus blacks,
whites versus Hindu's, whites versus blacks and
Hindu's, Hindu's versus the other ethnic groups. Pre-
vious studies on thrombolytic therapy in acute myo-
cardial infarction suggest that racial differences do
exist with an increased thrombolytic effect in blacks
accompanied by an increased risk of bleeding compli-
cations. The beneficial or detrimental effect of the
a d d i t i o n  o f  a n t i p l a t e l e t  t h e r a p y  t o  I V  r t - P a  m i g h t
therefore differ among different ethnic groups [24-
26].
Subgroup analyses consist will consist of a simple com-
parison of these different groups on primary and second-
ary outcome measures.
Ethical considerations
The ARTIS study will be conducted according to the
principles of the Declaration of Helsinki (version of 2004)
and in accordance with the Medical Research Involving
Human Subjects Act (WMO) and other guidelines, regu-
lations and Acts. The Medical Ethics Committee of the
Academic Medical Centre approved the protocol before
start of the trial. Data management, monitoring and
reporting of the study will be performed in accordance
with the ICH GCP guidelines. Approval by the local med-
ical ethical review board is required for each participating
centre before start of inclusion.
The AMC Medical Research BV has insurance, which is
in accordance with the legal requirements in The Nether-
lands (Article 7 WMO and the Measure regarding Com-
pulsory Insurance for Clinical Research in Humans of
June 23, 2003). This insurance provides cover for damage
to research subjects through injury or death caused by
the trial.
Publication policy
The trial results will be published by the coordinating
investigator on behalf of the ARTIS-study group. Mem-
bers of the ARTIS-study group will then be listed at the
end of the article.
Discussion
We present the protocol of a randomised controlled clini-
cal trial to investigate the efficacy of direct addition of
300 mg aspirin to rt-PA thrombolysis in acute ischemic
stroke. In accordance with thrombolysis in myocardial
infarction, in which the combination of acute aspirin and
thrombolysis improves outcome considerably [12], weZinkstok et al. Trials 2010, 11:51
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hypothesize that immediate platelet inhibition will
improve outcome in acute ischemic stoke by enhancing
thrombolysis and preventing re-occlusion after initial
recanalisation. As far as we know, this is the first clinical
trial investigating the efficacy of direct addition of aspirin
to intravenous rt-PA for acute ischemic stroke.
A major safety concern in this trial refers to the occur-
rence of symptomatic intracranial haemorrhage (SICH).
Subgroup-analysis of patients receiving APT within 24
hours after rt-PA thrombolysis in the first European
Cooperative Acute Stroke Study (ECASS-I) showed a
slight trend towards increased mortality from all causes
(including SICH). This risk is now explained by the
higher rt-PA dose (1.1 mg/kg) used in this trial since there
was no increased risk in ECASS-II where the currently
standard dosage of 0.9 mg/kg rt-PA was used [1].
Several cohort studies could not find a significant asso-
ciation between pre-treatment with antiplatelet agents
and SICH [27-30]. Other prospective observational stud-
ies observed even a net benefit in favourable outcome
after 3 months in patients using antiplatelet drugs prior
to rt-PA thrombolysis, despite a strong relationship
between this antiplatelet therapy and SICH [18,19].
Recent results from the large SITS-MOST registry of
more than 6,000 stroke patients treated with intravenous
rt-PA confirmed the increased risk of SICH in patients
with antiplatelet pre-treatment [31]. Previous use of aspi-
rin had an odds ratio of 1.58 (95% CI 1.04 - 2.39) of SICH
per SITS-MOST definition, a remote parenchymal haem-
orrhage type 2 on the 22 - 36 hours follow-up imaging
scans after the start of thrombolysis treatment. The clini-
cal relevance of these SICH remains to be determined
since independency and mortality within 3 months were
not associated with previous aspirin use in this registry.
Although prior antiplatelet therapy is a contra-indication
in this protocol, we are aware of the possible increased
risk of SICH due to the combination of rt-PA and aspirin.
Therefore, the DSMB will continuously monitor serious
adverse events in relation to efficacy outcome measures.
ARTIS is a randomised controlled trial investigating the
efficacy of the acute addition of aspirin to intravenous rt-
PA thrombolysis in patients with acute ischemic stroke.
ARTIS will answer a highly relevant question in acute
stroke care by means of a simple adjustment of current
antiplatelet regimen with regard to rt-PA thrombolysis. A
condensed version of the protocol has been published in
Cerebrovascular Diseases [32].
The ARTIS-Trial has started at the end of 2008. Thirty-
seven centres are actively randomizing patients. As of
May 10th 2010, 361 of the 800 patients have been included
so far . This trial is set up in the Netherlands. However ,
other centres - also from foreign countries - experienced
in thrombolysis are invited to participate as well. The
principle investigator can be contacted by e-mail.
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